Background:　High　cost　of　imported　pacemakers　is　a　main　obstacle　for　Chinese　patients　suffering　from　bradyarrhythmia,　and　a　domestically　developed　pacemaker　will　help　lower　the　burden.　This　study　aimed　to　evaluate　the　safety　and　efficacy　of　Qinming8631　DR　(Qinming　Medical,　Baoji,　China),　the　first　domestically　developed　dual-chamber　pacemaker　of　China,　compared　with　a　commercially　available　pacemaker　Talos　DR　(Biotronik,　Berlin,　Germany)　in　Chinese　patients.　Methods:　A　prospective　randomized　trial　was　conducted　at　14　centers　in　China.　Participants　were　randomized　into　trial　(Qinming8631　DR)　and　control　(Talos　DR)　groups.　Parameters　of　the　pacing　systems　were　collected　immediately　after　device　implantation　and　during　follow-ups.　The　effective　pacing　rate　at　6-month　follow-up　was　recorded　as　the　primary　end　point.　Electrical　properties,　magnet　response,　single-and　double-pole　polarity　conversion,　rate　response　function,　and　adverse　events　of　the　pacing　system　were　analyzed.　The　Cochran-Mantel-Haenszel　Chi-square　test,　paired　t-test,　and　Wilcoxon　signed-rank　test　were　used　for　measuring　primary　qualitative　outcomes　and　comparing　normally　and　abnormally　distributed　measurement　data.　Results:　A　total　of　225　patients　with　a　diagnosis　ofbradyarrhythmia　and　eligible　for　this　study　were　randomly　enrolled　into　the　trial　(n　=　113)　and　control　(n　=　112)　groups.　They　underwent　successful　pacemaker　implantation　with　acceptable　postoperative　pacing　threshold　and　sensitivity.　Effective　pacing　rates　of　trial　and　control　groups　were　comparable　both　in　the　full　analysis　set　and　the　per　protocol　set　(81.4%　vs.　79.5%,　P　=　0.712　and　95.4%　vs.　89.5%,　P=0.143,　respectively).　In　both　data　sets,　noninferiority　of　the　trial　group　was　above　the　predefined　noninferiority　limit(-9.5%).　Conclusions:　This　study　established　the　noninferiority　of　Qinming8631　DR　to　Talos　DR.　The　safety　and　efficacy　of　Qinming8631　DR　pacemaker　were　comparable　to　those　of　Talos　DR　in　treating　patients　with　cardiac　bradyarrhythmia.